Available Data. Bristol agrees to make available, at no charge, for the ACRPC’s use all data related to the agreement including any preliminary plans, maps, drawings, photographs, reports, traffic data, calculations, EDM, valuable papers, topographic survey, utility location plats, or any other pertinent public records.
Available Data. The Board agrees to make available to the Association, upon written request, all information in the public domain as outlined by the Open Public Records Acts.
Available Data. During negotiations, the Board and the Association shall present relevant data, exchange points of view and make proposals and counter-proposals. The Board shall make available to the Association for inspection all public records of the Springfield Township School District.
Available Data. Data will be provided for each individual project
Available Data. The following information will only be available to the consultant selected to perform the work: Existing prints will be available for use at the Office of Facilities Planning. Prints will not be allowed to leave the office. Arrangements can be made with the Office of Facilities Management (000) 000-0000 to copy existing prints at the consultant’s expense.
Available Data. The State has gathered and will make available a number of reference documents for Operators to review while conducting their due diligence in response to this RFQL. A complete list of available data is identified in Section 5, Reference Documents.
Available Data. All data for the GBM scenario will be collected within the HGG-2010 study; a phase IIb prospective placebo-controlled double blind randomized clinical trial for the treatment of patients with newly diagnosed glioblastoma multiforme with tumor vaccination as “add-on therapy” to standard primary treatment (EudraCT 2009-018228-14). For these data the informed consent is already available and the ethical approval is obtained (Commissie Ethische Ethiek van de Universitaire Ziekenhuizen KU Leuven, kenmerk: ML6285 from 1st of March 2010). All data will be shared and used according to the legal framework of CHIC. All patient data besides some specific immune therapy related data are stored within KWS (‘clinical working station’), the central data management application of the University Hospitals Leuven. The specific immune therapy related data are collected within an in-house managed FileMaker database for all HGG-IMMUNO-trials patients. A new in-house database will be provided where both data management applications are combined to gather all data for CHIC, i.e. data collected within the context of the HGG-2010 trial. Before usage is possible in CHIC, anonymization and pseudonymization procedures as well as data transfer issues are supervised via a trusted third party (legal and ethical framework of CHIC). Following data will be available for the GBM scenario: Clinical data: The clinical data of importance for the HGG-2010 trial are transferred from KWS, where all data are personally identified, to our in-house FileMaker database, where these data are pseudonymized via a unique number, and stored in a CRF. Clinical data of interest are: sex, age of diagnosis, date of diagnosis, weight, RPA classification according EORTC, presenting symptoms, date of resection, extent of resection, progression free survival, overall survival, relapse resection and relapse treatment. These data are gathered by clinical examination and by follow-up of each patient before, during and after treatment in the HGG-2010 protocol. Imaging data: Imaging studies in patients with GBM are performed at the time of diagnosis, (before and) after surgery and during adjuvant therapy. Magnetic resonance imaging (MRI) is the most commonly used imaging technique to document this pathology. Within CHIC, data from two different sources will be used. Firstly, we will provide data that are obtained in routine clinical setting. At multiple time points during the disease process, patients undergo an MRI sc...
Available Data. In order to assure a good data representativeness we selected two specific prostate cancer patient cohorts: radical prostatectomy and radical radiotherapy (RT). The patients, except a few, are treated in the geographical Italian region of Piedmont. Two observational retrospective studies, named EUREKA-1 and EUREKA-2 with reference to surgical and RT studies respectively, were explicitly authorized last July 2013 by the Ethical committee of the IRCCS Candiolo, lead institution of the clinical studies. A table of the clinical centres involved in the EUREKA-1 and EUREKA-2 studies is given below. EUREKA-1 (Radical Prostatectomy) EUREKA-2 (Radical Radiotherapy) Participating Hospital Town Participating Hospital Town Ospedale Molinette University Torino IRCCS Candiolo San Xxxxx Xxxxxxx University Orbassano Ospedale Maggiore University Novara Ospedale Maggiore University Novara San Xxxxx Xxxxxxx University Orbassano Ospedale San Xxxxxxxx Xxxxx Torino Ospedale Civile Ivrea Ospedale Santa Xxxxx Cuneo Ospedale degli Infermi Biella Ospedale Regionale Aosta Ospedale Cardinal Massaia Asti Ospedale Gradenigo Torino Istituto Europeo di Oncologia Milano Ospedale Cardinal Massaia Asti Osp. Santa Chiara University Pisa Ospedale Civile / ASL Torino 4 Ivrea / Cirié Ospedale Santissima Xxxxxxx Xxxxxxxxxxx Ospedale Xxxxx Xxxxxxxx Torino Ospedale Mauriziano Torino A common database platform, consisting in some tens of parameters recorded before and after treatment and recoverable either from paper or electronic clinical records, was devised. Depending on the available licenses and operator skills databases are filed using MS-Excel or MS-Access. All data will only be shared and used according to the legal framework of CHIC. Within this framework the data can be regarded as de-facto anonymous data. Each patient record is consecutively numbered and only the collecting center owns the ‘key’ connecting such number and the patient name. More details on the clinical studies are given: EUREKA-1 is a retrospective study on prostatectomysed patients, approved by Ethical Committee July 9th, 2013 (see Fig. 1), data collection started August 1st, 2013 and pertains to: anamnesis, diagnosis, biopsy, staging, radical prostatectomy and adjuvant therapies, pathology, clinical and serological follow-up, toxicity. Number of patients to be accrued: between 4000 and 4750. EUREKA-2 is a retrospective study on irradiated patients, approved by Ethical Committee July 9th, 2013, data collection started Au...
Available Data. Notwithstanding anything to the contrary herein, (i) Licensor may add, modify, remove, update, terminate access to, or otherwise change any Data made available hereunder at any time without notice in Licensor’s discretion, and (ii) Licensee’s rights with respect to any Data owned by third parties are further limited (in addition to the restrictions and limited permissions set forth herein) to the rights Licensor is permitted to grant to such Data under applicable agreements with such third parties and Licensee may be required to agree to additional terms and conditions applicable to such third party Data.
Available Data. All technical or other data relative to work in the possession of the Client or the Administrator shall be made available to the other party to this Agreement without expenses to the other party.
